← 產業報告目錄

Suppositories Market by Type (Urethral, Rectal, Vaginal), Base (Oleaginous, Aqueous, Emulsifying), Prescription (OTC, Prescribed), Application (Analgesic, Laxatives, Anti-fungal, Nasal Decongestants), Patient (Adult & Pediatrics) - Global Forecast to 2030

出版商 MarketsandMarkets產業別 Healthcare & Life Sciences出版日期 2025-08-01頁數 271報告編號 PH9446

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The global suppositories market is projected to reach USD 2.56 billion by 2030 from USD 1.63 billion in 2025, at a CAGR of 4.7% during the forecast period. The significant expansion of the geriatric demographic worldwide, coupled with the escalating prevalence of chronic conditions such as gastrointestinal diseases, hemorrhoids, and inflammatory bowel diseases, is poised to drive the demand for the suppositories market. Additionally, the increasing focus on preventive healthcare, coupled with rising healthcare expenditures and improvements in healthcare infrastructure across various regions, also facilitates market growth. Investments in healthcare infrastructure and initiatives to improve the accessibility and affordability of suppositories are also likely to bolster the market growth of suppositories. The rectal suppositories segment is expected to grow at the highest CAGR during the forecast period. The rectal suppositories segment is projected to grow with the highest CAGR in the suppositories market. The growth is primarily attributed to the effectiveness of the rectal suppositories in delivering rapid relief for common conditions such as pain, fever, inflammation, and constipation. They are widely used by geriatric and pediatric patients who often face swallowing problems. Moreover, the increasing demand for patient-friendly, targeted drug delivery formulations are boosting the adoption of rectal suppositories in various settings, thereby driving the market growth. The over-the-counter (OTC) segment is expected to command the highest CAGR during the forecast period. Based on prescription, the suppositories market is segmented into over-the-counter (OTC) and prescribed suppositories. The over-the-counter (OTC) segment is anticipated to grow at a faster rate due to increasing preferences for self-care solutions and easy accessibility of common treatment options. OTC suppositories, such as glycerin for constipation, and herbal hemorrhoid suppositories are widely available through retailers and online platforms. Moreover, increasing awareness about self-medication at home care increasingly demands OTC suppositories, thereby fueling the global market growth. The aqueous/hydrophilic base segment is expected to have the highest CAGR during the forecast period. The suppositories market by base is categorized into oleaginous/lipophilic bases, aqueous/hydrophilic bases, and emulsifying bases. The aqueous/ hydrophilic base segment accounted for the fastest growth rate during the forecast period. Compared to the traditional oleaginous (fat-based) bases, hydrophilic bases (e.g., polyethylene glycol (PEG) and glycerinated gelatins) provide a lot of flexibility and stability in formulations, especially for drugs that cannot tolerate melting. Hydrophilic bases are not greasy and constitute higher acceptability for the patient, driving their demand and market growth. North America accounted for the largest regional share of the suppositories market in 2024. The global suppositories market is segmented into five major regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America is the largest regional market for suppositories, whereas the Asia Pacific market is estimated to grow at the highest CAGR during the forecast period. The significant predominance of the North American market can largely be attributed to several interrelated factors. Firstly, a rising incidence of acute and chronic diseases has become a pressing public health concern and is driving demand for related healthcare services and products. This increase is further supported by a robust and well-established healthcare infrastructure that efficiently provides medical care and resources to address these health challenges. Furthermore, leading pharmaceutical companies and manufacturers based in the US and Canada drive consistent product availability and sustained-release technologies in the region. Together, these factors create a strong environment for market growth for suppositories. A breakdown of the primary participants referred to for this report is provided below: • By Company Type: Tier 1–35%, Tier 2–40%, and Tier 3– 25% • By Designation: C-level–30%, Director-level–23%, and Other Designations–47% • By Region: North America–35%, Europe–20%, Asia Pacific–25%, Latin America–13%, and Middle East & Africa–7% The major players operating in the suppositories market are Bayer AG (Germany), Novartis AG (Switzerland), Sanofi (France), Zydus Group (India), Bliss GVS Pharma Limited (India), Church & Dwight Co., Inc. (US), Bausch Health Companies Inc. (Canada), Teva Pharmaceutical Industries Ltd. (Israel), Sun Pharmaceutical Industries Ltd. (India), Adcock Ingram (South Africa), Aspen Holdings (South Africa), Julphar (UAE), Cipla (India), Haleon Group of Companies (UK), and Prestige Consumer Healthcare (US). Research Coverage This report studies the suppositories market based on type, base, prescription, application, patient type, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions). Reasons to Buy the Report The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to gain a larger market share. Firms purchasing the report could use one or a combination of the following strategies for strengthening their market presence. This report provides insights into the following points:  Analysis of key drivers (rise in prevalence of acute and chronic disorders, rapidly expanding global aging population and subsequent surge in chronic disorders, ability to bypass the hepatic first-pass metabolism and therapeutic advantages, and growing demand for targeted drug delivery solutions), restraints (stringent regulatory requirements, development of innovative and more targeted drug delivery technologies, low patient and caregiver acceptance), opportunities (advancements in formulation technologies to offer high-growth opportunities, and expanding therapeutic applications), challenges (complexity of formulation and drug delivery, and limited shelf life of suppositories)  Market Penetration: Comprehensive information on the product portfolios offered by the top players in the suppositories market  Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the suppositories market  Market Development: Comprehensive information on lucrative emerging regions  Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the suppositories market  Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.
目錄 Table of Contents
1 INTRODUCTION 25 1.1 STUDY OBJECTIVES 25 1.2 MARKET DEFINITION 25 1.3 STUDY SCOPE 26 1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE 26 1.3.2 INCLUSIONS AND EXCLUSIONS 27 1.3.3 YEARS CONSIDERED 28 1.4 CURRENCY CONSIDERED 28 1.5 STAKEHOLDERS 29 2 RESEARCH METHODOLOGY 30 2.1 RESEARCH DATA 30 2.1.1 SECONDARY DATA 31 2.1.1.1 Key data from secondary sources 32 2.1.2 PRIMARY DATA 32 2.1.2.1 Primary sources 33 2.1.2.2 Key industry insights 34 2.1.2.3 Breakdown of primary interviews 34 2.2 MARKET SIZE ESTIMATION 35 2.2.1 REVENUE SHARE ANALYSIS (BOTTOM-UP APPROACH) 36 2.2.2 COMPANY INVESTOR PRESENTATIONS AND PRIMARY INTERVIEWS 36 2.2.3 TOP-DOWN APPROACH 37 2.2.4 BOTTOM-UP APPROACH 37 2.2.5 PRIMARY INTERVIEWS 38 2.3 GROWTH FORECAST MODEL 38 2.4 DATA TRIANGULATION 39 2.5 RESEARCH ASSUMPTIONS 40 2.6 RESEARCH LIMITATIONS 40 2.7 RISK ANALYSIS 41 3 EXECUTIVE SUMMARY 42 4 PREMIUM INSIGHTS 46 4.1 SUPPOSITORIES MARKET OVERVIEW 46 4.2 NORTH AMERICA: SUPPOSITORIES MARKET, BY TYPE AND COUNTRY 47 4.3 SUPPOSITORIES MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION) 47 4.4 SUPPOSITORIES MARKET, BY BASE, 2025 VS. 2030 (USD MILLION) 48 4.5 SUPPOSITORIES MARKET, BY PRESCRIPTION, 2025 VS. 2030 (USD MILLION) 48 4.6 SUPPOSITORIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 49 5 MARKET OVERVIEW 50 5.1 INTRODUCTION 50 5.2 MARKET DYNAMICS 50 5.2.1 DRIVERS 51 5.2.1.1 Increasing prevalence of acute and chronic disorders 51 5.2.1.2 Booming geriatric population worldwide 51 5.2.1.3 Pharmacokinetic advantages of suppositories 52 5.2.1.4 Growing demand for targeted and localized drug delivery solutions 52 5.2.2 RESTRAINTS 53 5.2.2.1 Stringent regulatory requirements 53 5.2.2.2 Rapid development of innovative drug delivery technologies 53 5.2.2.3 Low patient and caregiver acceptance 54 5.2.3 OPPORTUNITIES 54 5.2.3.1 Emerging formulations and 3D techniques 54 5.2.3.2 Expanding therapeutic applications 54 5.2.4 CHALLENGES 55 5.2.4.1 Complex formulation and drug delivery 55 5.2.4.2 Limited shelf life of suppositories 55 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 56 5.4 PRICING ANALYSIS 56 5.4.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER 56 5.4.2 AVERAGE SELLING PRICE TREND, BY REGION 58 5.5 VALUE CHAIN ANALYSIS 58 5.6 ECOSYSTEM ANALYSIS 60 5.7 INVESTMENT AND FUNDING SCENARIO 61 5.8 TECHNOLOGY ANALYSIS 62 5.8.1 KEY TECHNOLOGIES 62 5.8.1.1 3D printed multi-drug-loaded suppositories 62 5.8.1.2 Self-microemulsifying suppository systems 63 5.8.2 COMPLEMENTARY TECHNOLOGIES 63 5.8.2.1 Mucoadhesive and bioadhesive polymers 63 5.8.3 ADJACENT TECHNOLOGIES 64 5.8.3.1 Form-fill-seal (FFS) machine technology 64 5.9 PATENT ANALYSIS 64 5.9.1 PATENT PUBLICATION TRENDS FOR SUPPOSITORIES 64 5.9.2 JURISDICTION AND TOP APPLICANT ANALYSIS 66 5.10 TRADE ANALYSIS 67 5.10.1 IMPORT DATA 67 5.10.2 EXPORT DATA 68   5.11 KEY CONFERENCES AND EVENTS, 2025–2026 68 5.12 REGULATORY LANDSCAPE 69 5.12.1 REGULATORY FRAMEWORK 69 5.12.1.1 North America 69 5.12.1.1.1 US 69 5.12.1.1.2 Canada 70 5.12.1.2 Europe 70 5.12.1.2.1 Germany 70 5.12.1.2.2 Italy 70 5.12.1.2.3 France 70 5.12.1.2.4 UK 70 5.12.1.3 Asia Pacific 71 5.12.1.3.1 China 71 5.12.1.3.2 Japan 71 5.12.1.3.3 India 71 5.12.1.3.4 South Korea 71 5.12.1.3.5 Australia 71 5.12.1.4 Latin America 72 5.12.1.5 Middle East & Africa 72 5.12.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 72 5.13 PORTER’S FIVE FORCES ANALYSIS 75 5.13.1 BARGAINING POWER OF SUPPLIERS 76 5.13.2 BARGAINING POWER OF BUYERS 76 5.13.3 THREAT OF NEW ENTRANTS 76 5.13.4 THREAT OF SUBSTITUTES 76 5.13.5 INTENSITY OF COMPETITIVE RIVALRY 77 5.14 KEY STAKEHOLDERS AND BUYING CRITERIA 77 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 77 5.14.2 KEY BUYING CRITERIA 78 5.15 UNMET NEEDS/END-USER EXPECTATIONS 79 5.16 IMPACT OF AI/GEN AI 80 5.16.1 INTRODUCTION 80 5.16.2 MARKET POTENTIAL OF AI ON SUPPOSITORIES MARKET 80 5.16.3 AI USE CASES 81 5.16.4 FUTURE OF GENERATIVE AI IN SUPPOSITORIES MARKET 81 5.17 IMPACT OF 2025 US TARIFF 82 5.17.1 INTRODUCTION 82 5.17.2 KEY TARIFF RATES 83 5.17.3 PRICE IMPACT ANALYSIS 84 5.17.4 IMPACT ON COUNTRY/REGION 84 5.17.5 IMPACT ON END-USER INDUSTRIES 85 6 SUPPOSITORIES MARKET, BY TYPE 86 6.1 INTRODUCTION 87 6.2 RECTAL SUPPOSITORIES 87 6.2.1 EASE OF USE, AFFORDABILITY, AND QUICK RELIEF TO PROMOTE GROWTH 87 6.3 VAGINAL SUPPOSITORIES 89 6.3.1 SHORT-TERM THERAPY AND QUICK SYMPTOM RELIEF TO AUGMENT GROWTH 89 6.4 URETHRAL SUPPOSITORIES 92 6.4.1 NEED FOR LOCALIZED, FAST-ACTING THERAPY TO CONTRIBUTE TO GROWTH 92 7 SUPPOSITORIES MARKET, BY BASE 94 7.1 INTRODUCTION 95 7.2 OLEAGINOUS/ LIPOPHILIC BASES 95 7.2.1 RISING PATIENT PREFERENCE FOR EASY-TO-USE, NON-ORAL DOSAGE FORMS TO FACILITATE GROWTH 95 7.3 AQUEOUS/HYDROPHILIC BASES 96 7.3.1 NEED TO MAINTAIN DRUG STABILITY TO SPUR GROWTH 96 7.4 EMULSIFYING BASES 98 7.4.1 CONSISTENT DRUG RELEASE AND ABSORPTION TO BOLSTER GROWTH 98 8 SUPPOSITORIES MARKET, BY PRESCRIPTION 100 8.1 INTRODUCTION 101 8.2 PRESCRIBED SUPPOSITORIES 101 8.2.1 INCREASED RELIANCE ON PRESCRIPTION SUPPOSITORIES FOR HORMONE REPLACEMENT AND ANTIEMETIC TREATMENT TO SUPPORT GROWTH 101 8.3 OVER-THE-COUNTER SUPPOSITORIES 103 8.3.1 GROWING PREFERENCE FOR CONVENIENT, NON-INVASIVE RELIEF FROM COMMON HEALTH CONCERNS TO FUEL MARKET 103 9 SUPPOSITORIES MARKET, BY APPLICATION 105 9.1 INTRODUCTION 106 9.2 HEMORRHOID TREATMENTS 106 9.2.1 INCREASING OBESITY AND SEDENTARY LIFESTYLE TO EXPEDITE GROWTH 106 9.3 ANTI-BACTERIAL AND ANTI-FUNGAL APPLICATIONS 107 9.3.1 GROWING BURDEN OF VAGINAL INFECTIONS TO PROPEL MARKET 107 9.4 ANALGESICS & ANTIPYRETICS 109 9.4.1 INCREASING INCIDENCE OF CHRONIC PAIN CONDITIONS TO ACCELERATE GROWTH 109 9.5 LAXATIVES 110 9.5.1 LOW DIETARY FIBER INTAKE AND RISING PREVALENCE OF CONSTIPATION TO BOOST MARKET 110 9.6 ANTI-EMETICS 112 9.6.1 GROWING USE OF ANTI-EMETIC SUPPOSITORIES FOR CHEMOTHERAPY, RADIATION THERAPY, OR POST-OPERATIVE RECOVERY TO DRIVE MARKET 112 9.7 OTHER APPLICATIONS 113 10 SUPPOSITORIES MARKET, BY PATIENT TYPE 115 10.1 INTRODUCTION 116 10.2 ADULT PATIENTS 116 10.2.1 GROWING FOCUS ON CHRONIC CONDITION MANAGEMENT TO DRIVE MARKET 116 10.3 PEDIATRIC PATIENTS 117 10.3.1 INCREASING NEED FOR ALTERNATIVE DRUG DELIVERY TO SUPPORT GROWTH 117 10.4 GERIATRIC PATIENTS 119 10.4.1 NEED FOR RELIABLE, EFFECTIVE, AND WELL-TOLERATED DRUG DELIVERY IN ELDERLY PATIENTS TO AID GROWTH 119 11 SUPPOSITORIES MARKET, BY REGION 121 11.1 INTRODUCTION 122 11.2 NORTH AMERICA 123 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 123 11.2.2 US 126 11.2.2.1 Rising demand for non-oral therapeutics among aging and chronic patient groups to augment growth 126 11.2.3 CANADA 129 11.2.3.1 Government support and public health campaigns to encourage growth 129 11.3 EUROPE 131 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 131 11.3.2 GERMANY 134 11.3.2.1 High healthcare spending and prescription culture to support growth 134 11.3.3 FRANCE 136 11.3.3.1 Increasing use of suppositories in pediatrics, gynecology, and internal medicine to propel market 136 11.3.4 UK 138 11.3.4.1 Growing use of suppositories for pediatric fever, antiemetic needs, and constipation management to drive market 138 11.3.5 ITALY 141 11.3.5.1 Increasing pediatric patient population to contribute to growth 141 11.3.6 SPAIN 143 11.3.6.1 Rising adoption of non-invasive, self-administered dosage forms to spur growth 143 11.3.7 REST OF EUROPE 145 11.4 ASIA PACIFIC 148 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 148 11.4.2 JAPAN 152 11.4.2.1 Geriatric population and regulatory guidelines to drive market 152   11.4.3 CHINA 154 11.4.3.1 Expanding elderly population to boost market 154 11.4.4 INDIA 156 11.4.4.1 Increasing healthcare penetration across urban and semi-urban areas to promote growth 156 11.4.5 AUSTRALIA 159 11.4.5.1 Increased patient volume and favorable government initiatives to sustain growth 159 11.4.6 SOUTH KOREA 161 11.4.6.1 Favorable insurance policy to accelerate growth 161 11.4.7 REST OF ASIA PACIFIC 163 11.5 LATIN AMERICA 165 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 165 11.5.2 BRAZIL 168 11.5.2.1 Expanding public healthcare access and domestic manufacturing to bolster growth 168 11.5.3 MEXICO 170 11.5.3.1 Growing consumer preference for self-medication to propel market 170 11.5.4 REST OF LATIN AMERICA 172 11.6 MIDDLE EAST & AFRICA 175 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 175 11.6.2 GCC COUNTRIES 177 11.6.2.1 Kingdom of Saudi Arabia (KSA) 180 11.6.2.1.1 Substantial public healthcare investment to facilitate growth 180 11.6.2.2 United Arab Emirates (UAE) 182 11.6.2.2.1 Favorable environment for drug import and local manufacturing to aid growth 182 11.6.2.3 Rest of GCC Countries 184 11.6.3 REST OF MIDDLE EAST & AFRICA 186 12 COMPETITIVE LANDSCAPE 189 12.1 INTRODUCTION 189 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 189 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN SUPPOSITORIES MARKET 189 12.3 REVENUE ANALYSIS, 2022–2024 191 12.4 MARKET SHARE ANALYSIS, 2024 191 12.5 BRAND/PRODUCT COMPARISON 194 12.6 COMPANY VALUATION AND FINANCIAL METRICS 195 12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 196 12.7.1 STARS 196 12.7.2 EMERGING LEADERS 196 12.7.3 PERVASIVE PLAYERS 196 12.7.4 PARTICIPANTS 196 12.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 198 12.7.5.1 Company footprint 198 12.7.5.2 Region footprint 198 12.7.5.3 Type footprint 199 12.7.5.4 Base footprint 200 12.7.5.5 Prescription footprint 201 12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 202 12.8.1 PROGRESSIVE COMPANIES 202 12.8.2 RESPONSIVE COMPANIES 202 12.8.3 DYNAMIC COMPANIES 202 12.8.4 STARTING BLOCKS 202 12.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 204 12.8.5.1 Detailed list of key startups/SMEs 204 12.8.5.2 Competitive benchmarking of key startups/SMEs 204 12.9 COMPETITIVE SCENARIO 205 12.9.1 PRODUCT APPROVALS 205 12.9.2 DEALS 205 12.9.3 EXPANSIONS 206 13 COMPANY PROFILES 207 13.1 KEY PLAYERS 207 13.1.1 SANDOZ GROUP AG 207 13.1.1.1 Business overview 207 13.1.1.2 Products offered 208 13.1.1.3 MnM view 209 13.1.1.3.1 Key strengths 209 13.1.1.3.2 Strategic choices 209 13.1.1.3.3 Weaknesses and competitive threats 209 13.1.2 TEVA PHARMACEUTICAL INDUSTRIES LTD. 210 13.1.2.1 Business overview 210 13.1.2.2 Products offered 211 13.1.2.3 MnM view 212 13.1.2.3.1 Key strengths 212 13.1.2.3.2 Strategic choices 212 13.1.2.3.3 Weaknesses and competitive threats 212 13.1.3 CIPLA 213 13.1.3.1 Business overview 213 13.1.3.2 Products offered 214 13.1.3.3 MnM view 215 13.1.3.3.1 Key strengths 215 13.1.3.3.2 Strategic choices 215 13.1.3.3.3 Weaknesses and competitive threats 215 13.1.4 SANOFI 216 13.1.4.1 Business overview 216 13.1.4.2 Products offered 217 13.1.4.3 Recent developments 218 13.1.4.3.1 Deals 218 13.1.4.4 MnM view 218 13.1.4.4.1 Key strengths 218 13.1.4.4.2 Strategic choices 218 13.1.4.4.3 Weaknesses and competitive threats 218 13.1.5 SUN PHARMACEUTICAL INDUSTRIES LTD. 219 13.1.5.1 Business overview 219 13.1.5.2 Products offered 220 13.1.5.3 Recent developments 221 13.1.5.3.1 Deals 221 13.1.5.4 MnM view 221 13.1.5.4.1 Key strengths 221 13.1.5.4.2 Strategic choices 221 13.1.5.4.3 Weaknesses and competitive threats 221 13.1.6 BAYER AG 222 13.1.6.1 Business overview 222 13.1.6.2 Products offered 223 13.1.6.3 Recent developments 224 13.1.6.3.1 Expansions 224 13.1.7 NOVARTIS AG 225 13.1.7.1 Business overview 225 13.1.7.2 Products offered 226 13.1.7.3 Recent developments 227 13.1.7.3.1 Deals 227 13.1.8 ZYDUS GROUP 228 13.1.8.1 Business overview 228 13.1.8.2 Products offered 229 13.1.8.3 Recent developments 230 13.1.8.3.1 Product approvals 230 13.1.9 BLISS GVS PHARMA LIMITED 231 13.1.9.1 Business overview 231 13.1.9.2 Products offered 232 13.1.10 CHURCH & DWIGHT CO., INC. 233 13.1.10.1 Business overview 233 13.1.10.2 Products offered 234   13.1.11 BAUSCH HEALTH COMPANIES INC. 235 13.1.11.1 Business overview 235 13.1.11.2 Products offered 237 13.1.12 ADCOCK INGRAM 238 13.1.12.1 Business overview 238 13.1.12.2 Products offered 239 13.1.13 ASPEN HOLDINGS 240 13.1.13.1 Business overview 240 13.1.13.2 Products offered 241 13.1.14 JULPHAR 242 13.1.14.1 Business overview 242 13.1.14.2 Products offered 243 13.1.15 HALEON GROUP OF COMPANIES 245 13.1.15.1 Business overview 245 13.1.15.2 Products offered 246 13.1.16 LES LABORATOIRES SERVIER 247 13.1.16.1 Business overview 247 13.1.16.2 Products offered 248 13.1.17 PRESTIGE CONSUMER HEALTHCARE INC. 249 13.1.17.1 Business overview 249 13.1.17.2 Products offered 250 13.1.18 VIATRIS INC. 252 13.1.18.1 Business overview 252 13.1.18.2 Products offered 253 13.1.19 GALEN LIMITED 254 13.1.19.1 Business overview 254 13.1.19.2 Products offered 254 13.1.20 MERIDIAN ENTERPRISES PVT. LTD. 257 13.1.20.1 Business overview 257 13.1.20.2 Products offered 257 13.2 OTHER PLAYERS 259 13.2.1 COSETTE PHARMACEUTICALS 259 13.2.2 FLAGSHIP 260 13.2.3 OUBARI PHARMA 261 13.2.4 LAVINA PHARMACEUTICALS PVT. LTD. 262 13.2.5 NORWELL 263   14 APPENDIX 264 14.1 DISCUSSION GUIDE 264 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 267 14.3 CUSTOMIZATION OPTIONS 269 14.4 RELATED REPORTS 269 14.5 AUTHOR DETAILS 270
圖表清單 List of Tables & Figures
TABLE 1 SUPPOSITORIES MARKET: INCLUSIONS AND EXCLUSIONS 27 TABLE 2 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD, 2021–2024 28 TABLE 3 SUPPOSITORIES MARKET: RESEARCH ASSUMPTIONS 40 TABLE 4 SUPPOSITORIES MARKET: RISK ANALYSIS 41 TABLE 5 AVERAGE SELLING PRICE TREND OF RECTAL SUPPOSITORIES, BY KEY PLAYER, 2023–2025 (USD) 57 TABLE 6 AVERAGE SELLING PRICE TREND OF RECTAL SUPPOSITORIES, BY REGION, 2023–2025 (USD) 58 TABLE 7 SUPPOSITORIES MARKET: ROLE OF COMPANIES IN ECOSYSTEM 61 TABLE 8 SUPPOSITORIES MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2023–2025 66 TABLE 9 IMPORT DATA FOR HS CODE 3006, BY COUNTRY, 2021–2024 (USD THOUSAND) 67 TABLE 10 EXPORT DATA FOR HS CODE 3006, BY COUNTRY, 2021–2024 (USD THOUSAND) 68 TABLE 11 SUPPOSITORIES MARKET: KEY CONFERENCES AND EVENTS, 2025–2026 68 TABLE 12 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 72 TABLE 13 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 73 TABLE 14 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 74 TABLE 15 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 74 TABLE 16 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 75 TABLE 17 SUPPOSITORIES MARKET: PORTER’S FIVE FORCES ANALYSIS 76 TABLE 18 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE (%) 77 TABLE 19 KEY BUYING CRITERIA, BY TYPE 78 TABLE 20 SUPPOSITORIES MARKET: CURRENT UNMET NEEDS 79 TABLE 21 US-ADJUSTED RECIPROCAL TARIFF RATES 83 TABLE 22 KEY PRODUCT-RELATED TARIFF EFFECTIVE FOR SUPPOSITORIES 83 TABLE 23 IMPACT ON COUNTRY/ REGION DUE TO US TARIFFS 84 TABLE 24 SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 87 TABLE 25 KEY PLAYERS PROVIDING RECTAL SUPPOSITORIES 88 TABLE 26 RECTAL SUPPOSITORIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 89 TABLE 27 KEY PLAYERS PROVIDING VAGINAL SUPPOSITORIES 90 TABLE 28 VAGINAL SUPPOSITORIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 91 TABLE 29 KEY PLAYERS PROVIDING URETHRAL SUPPOSITORIES 92 TABLE 30 URETHRAL SUPPOSITORIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 93 TABLE 31 SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION) 95 TABLE 32 SUPPOSITORIES MARKET FOR OLEAGINOUS/LIPOPHILIC BASES, BY COUNTRY, 2023–2030 (USD MILLION) 96 TABLE 33 SUPPOSITORIES MARKET FOR AQUEOUS/HYDROPHILIC BASES, BY COUNTRY, 2023–2030 (USD MILLION) 97 TABLE 34 SUPPOSITORIES MARKET FOR EMULSIFYING BASES, BY COUNTRY, 2023–2030 (USD MILLION) 99 TABLE 35 SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION) 101 TABLE 36 KEY PLAYERS PROVIDING PRESCRIBED SUPPOSITORIES 101 TABLE 37 PRESCRIBED SUPPOSITORIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 102 TABLE 38 KEY PLAYERS PROVIDING OVER-THE-COUNTER (OTC) SUPPOSITORIES 103 TABLE 39 OVER-THE-COUNTER (OTC) SUPPOSITORIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 104 TABLE 40 SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 106 TABLE 41 SUPPOSITORIES MARKET FOR HEMORRHOID TREATMENTS, BY COUNTRY, 2023–2030 (USD MILLION) 107 TABLE 42 SUPPOSITORIES MARKET FOR ANTI-BACTERIAL & ANTI-FUNGAL APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 108 TABLE 43 SUPPOSITORIES MARKET FOR ANALGESICS & ANTIPYRETICS, BY COUNTRY, 2023–2030 (USD MILLION) 110 TABLE 44 SUPPOSITORIES MARKET FOR LAXATIVES, BY COUNTRY, 2023–2030 (USD MILLION) 111 TABLE 45 SUPPOSITORIES MARKET FOR ANTI-EMETICS, BY COUNTRY, 2023–2030 (USD MILLION) 113 TABLE 46 SUPPOSITORIES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 114 TABLE 47 SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION) 116 TABLE 48 SUPPOSITORIES MARKET FOR ADULT PATIENTS, BY COUNTRY, 2023–2030 (USD MILLION) 117 TABLE 49 SUPPOSITORIES MARKET FOR PEDIATRIC PATIENTS, BY COUNTRY, 2023–2030 (USD MILLION) 118 TABLE 50 SUPPOSITORIES MARKET FOR GERIATRIC PATIENTS, BY COUNTRY, 2023–2030 (USD MILLION) 120 TABLE 51 SUPPOSITORIES MARKET, BY REGION, 2023–2030 (USD MILLION) 122 TABLE 52 SUPPOSITORIES MARKET FOR PRESCRIPTION, BY REGION, 2023–2030 (THOUSAND UNITS) 123 TABLE 53 NORTH AMERICA: SUPPOSITORIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 124 TABLE 54 NORTH AMERICA: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 125 TABLE 55 NORTH AMERICA: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION) 125 TABLE 56 NORTH AMERICA: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION) 125 TABLE 57 NORTH AMERICA: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 126 TABLE 58 NORTH AMERICA: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION) 126 TABLE 59 US: KEY MACROECONOMIC INDICATORS 127 TABLE 60 US: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 127 TABLE 61 US: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION) 127 TABLE 62 US: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION) 128 TABLE 63 US: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 128 TABLE 64 US: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION) 128 TABLE 65 CANADA: KEY MACROECONOMIC INDICATORS 129 TABLE 66 CANADA: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 129 TABLE 67 CANADA: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION) 130 TABLE 68 CANADA: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION) 130 TABLE 69 CANADA: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 130 TABLE 70 CANADA: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION) 131 TABLE 71 EUROPE: SUPPOSITORIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 132 TABLE 72 EUROPE: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 132 TABLE 73 EUROPE: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION) 132 TABLE 74 EUROPE: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION) 133 TABLE 75 EUROPE: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 133 TABLE 76 EUROPE: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION) 133 TABLE 77 GERMANY: KEY MACROECONOMIC INDICATORS 134 TABLE 78 GERMANY: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 134 TABLE 79 GERMANY: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION) 135 TABLE 80 GERMANY: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION) 135 TABLE 81 GERMANY: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 135 TABLE 82 GERMANY: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION) 136 TABLE 83 FRANCE: KEY MACROECONOMIC INDICATORS 136 TABLE 84 FRANCE: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 137 TABLE 85 FRANCE: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION) 137 TABLE 86 FRANCE: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION) 137 TABLE 87 FRANCE: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 138 TABLE 88 FRANCE: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION) 138 TABLE 89 UK: KEY MACROECONOMIC INDICATORS 139 TABLE 90 UK: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 139 TABLE 91 UK: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION) 139 TABLE 92 UK: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION) 140 TABLE 93 UK: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 140 TABLE 94 UK: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION) 140 TABLE 95 ITALY: KEY MACROECONOMIC INDICATORS 141 TABLE 96 ITALY: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 141 TABLE 97 ITALY: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION) 142 TABLE 98 ITALY: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION) 142 TABLE 99 ITALY: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION 142 TABLE 100 ITALY: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION) 143 TABLE 101 SPAIN: KEY MACROECONOMIC INDICATORS 143 TABLE 102 SPAIN: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 144 TABLE 103 SPAIN: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION) 144 TABLE 104 SPAIN: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION) 144 TABLE 105 SPAIN: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 145 TABLE 106 SPAIN: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION) 145 TABLE 107 REST OF EUROPE: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 146 TABLE 108 REST OF EUROPE: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION) 146 TABLE 109 REST OF EUROPE: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION) 146 TABLE 110 REST OF EUROPE: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 147 TABLE 111 REST OF EUROPE: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION) 147 TABLE 112 ASIA PACIFIC: SUPPOSITORIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 150 TABLE 113 ASIA PACIFIC: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 150 TABLE 114 ASIA PACIFIC: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION) 150 TABLE 115 ASIA PACIFIC: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION) 151 TABLE 116 ASIA PACIFIC: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 151 TABLE 117 ASIA PACIFIC: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION) 151 TABLE 118 JAPAN: KEY MACROECONOMIC INDICATORS 152 TABLE 119 JAPAN: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 152 TABLE 120 JAPAN: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION) 153 TABLE 121 JAPAN: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION) 153 TABLE 122 JAPAN: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 153 TABLE 123 JAPAN: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION) 154 TABLE 124 CHINA: KEY MACROECONOMIC INDICATORS 154 TABLE 125 CHINA: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 155 TABLE 126 CHINA: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION) 155 TABLE 127 CHINA: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION) 155 TABLE 128 CHINA: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 156 TABLE 129 CHINA: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION) 156 TABLE 130 INDIA: KEY MACROECONOMIC INDICATORS 157 TABLE 131 INDIA: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 157 TABLE 132 INDIA: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION) 157 TABLE 133 INDIA: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION) 158 TABLE 134 INDIA: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 158 TABLE 135 INDIA: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION) 158 TABLE 136 AUSTRALIA: KEY MACROECONOMIC INDICATORS 159 TABLE 137 AUSTRALIA: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 159 TABLE 138 AUSTRALIA: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION) 160 TABLE 139 AUSTRALIA: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION) 160 TABLE 140 AUSTRALIA: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 160 TABLE 141 AUSTRALIA: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION) 161 TABLE 142 SOUTH KOREA: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 161 TABLE 143 SOUTH KOREA: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION) 162 TABLE 144 SOUTH KOREA: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION) 162 TABLE 145 SOUTH KOREA: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 162 TABLE 146 SOUTH KOREA: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION) 163 TABLE 147 REST OF ASIA PACIFIC: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 163 TABLE 148 REST OF ASIA PACIFIC: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION) 164 TABLE 149 REST OF ASIA PACIFIC: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION) 164 TABLE 150 REST OF ASIA PACIFIC: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 164 TABLE 151 REST OF ASIA PACIFIC: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION) 165 TABLE 152 LATIN AMERICA: SUPPOSITORIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 166 TABLE 153 LATIN AMERICA: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 166 TABLE 154 LATIN AMERICA: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION) 166 TABLE 155 LATIN AMERICA: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION) 167 TABLE 156 LATIN AMERICA: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 167 TABLE 157 LATIN AMERICA: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION) 167 TABLE 158 BRAZIL: KEY MACROECONOMIC INDICATORS 168 TABLE 159 BRAZIL: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 168 TABLE 160 BRAZIL: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION) 169 TABLE 161 BRAZIL: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION) 169 TABLE 162 BRAZIL: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 169 TABLE 163 BRAZIL: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION) 170 TABLE 164 MEXICO: KEY MACROECONOMIC INDICATORS 170 TABLE 165 MEXICO: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 171 TABLE 166 MEXICO: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION) 171 TABLE 167 MEXICO: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION) 171 TABLE 168 MEXICO: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 172 TABLE 169 MEXICO: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION) 172 TABLE 170 REST OF LATIN AMERICA: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 173 TABLE 171 REST OF LATIN AMERICA: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION) 173 TABLE 172 REST OF LATIN AMERICA: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION) 173 TABLE 173 REST OF LATIN AMERICA: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 174 TABLE 174 REST OF LATIN AMERICA: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION) 174 TABLE 175 MIDDLE EAST & AFRICA: SUPPOSITORIES MARKET, BY REGION, 2023–2030 (USD MILLION) 175 TABLE 176 MIDDLE EAST & AFRICA: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 176 TABLE 177 MIDDLE EAST & AFRICA: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION) 176 TABLE 178 MIDDLE EAST & AFRICA: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION) 176 TABLE 179 MIDDLE EAST & AFRICA: SUPPOSITORIES MARKET, BY APPLICATION 2023–2030 (USD MILLION) 177 TABLE 180 MIDDLE EAST & AFRICA: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION) 177 TABLE 181 GCC COUNTRIES: SUPPOSITORIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 178 TABLE 182 GCC COUNTRIES: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 178 TABLE 183 GCC COUNTRIES: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION) 178 TABLE 184 GCC COUNTRIES: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION) 179 TABLE 185 GCC COUNTRIES: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 179 TABLE 186 GCC COUNTRIES: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION) 179 TABLE 187 KINGDOM OF SAUDI ARABIA (KSA): KEY MACROECONOMIC INDICATORS 180 TABLE 188 KINGDOM OF SAUDI ARABIA (KSA): SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 180 TABLE 189 KINGDOM OF SAUDI ARABIA (KSA): SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION) 181 TABLE 190 KINGDOM OF SAUDI ARABIA (KSA): SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION) 181 TABLE 191 KINGDOM OF SAUDI ARABIA (KSA): SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 181 TABLE 192 KINGDOM OF SAUDI ARABIA (KSA): SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION) 182 TABLE 193 UAE: KEY MACROECONOMIC INDICATORS 182 TABLE 194 UAE: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 183 TABLE 195 UAE: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION) 183 TABLE 196 UAE: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION) 183 TABLE 197 UAE: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 184 TABLE 198 UAE: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION) 184 TABLE 199 REST OF GCC COUNTRIES: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 185 TABLE 200 REST OF GCC COUNTRIES: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION) 185 TABLE 201 REST OF GCC COUNTRIES: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION) 185 TABLE 202 REST OF GCC COUNTRIES: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 186 TABLE 203 REST OF GCC COUNTRIES: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION) 186 TABLE 204 REST OF MIDDLE EAST & AFRICA: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 187 TABLE 205 REST OF MIDDLE EAST & AFRICA: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION) 187 TABLE 206 REST OF MIDDLE EAST & AFRICA: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION) 187 TABLE 207 REST OF MIDDLE EAST & AFRICA: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 188 TABLE 208 REST OF MIDDLE EAST & AFRICA: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION) 188 TABLE 209 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN SUPPOSITORIES MARKET 189 TABLE 210 SUPPOSITORIES MARKET: DEGREE OF COMPETITION, 2024 192 TABLE 211 SUPPOSITORIES MARKET: REGION FOOTPRINT 198 TABLE 212 SUPPOSITORIES MARKET: TYPE FOOTPRINT 199 TABLE 213 SUPPOSITORIES MARKET: BASE FOOTPRINT 200 TABLE 214 SUPPOSITORIES MARKET: PRESCRIPTION FOOTPRINT 201 TABLE 215 SUPPOSITORIES MARKET: DETAILED LIST OF KEY STARTUPS/SMES 204 TABLE 216 SUPPOSITORIES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 204 TABLE 217 SUPPOSITORIES MARKET: PRODUCT APPROVALS, JANUARY 2022–MAY 2025 205 TABLE 218 SUPPOSITORIES MARKET: DEALS, JANUARY 2022–MAY 2025 205 TABLE 219 SUPPOSITORIES MARKET: EXPANSIONS, JANUARY 2022–MAY 2025 206 TABLE 220 SANDOZ GROUP AG: COMPANY OVERVIEW 207 TABLE 221 SANDOZ GROUP AG: PRODUCTS OFFERED 208 TABLE 222 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW 210 TABLE 223 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED 211 TABLE 224 CIPLA: COMPANY OVERVIEW 213 TABLE 225 CIPLA: PRODUCTS OFFERED 214 TABLE 226 SANOFI: COMPANY OVERVIEW 216 TABLE 227 SANOFI: PRODUCTS OFFERED 217 TABLE 228 SANOFI: DEALS, JANUARY 2022–MAY 2025 218 TABLE 229 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW 219 TABLE 230 SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED 220 TABLE 231 SUN PHARMACEUTICAL INDUSTRIES LTD.: DEALS, JANUARY 2022–MAY 2025 221 TABLE 232 BAYER AG: COMPANY OVERVIEW 222 TABLE 233 BAYER AG: PRODUCTS OFFERED 223 TABLE 234 BAYER AG: EXPANSIONS, JANUARY 2022–MAY 2025 224 TABLE 235 NOVARTIS AG: COMPANY OVERVIEW 225 TABLE 236 NOVARTIS AG: PRODUCTS OFFERED 226 TABLE 237 NOVARTIS AG: DEALS, JANUARY 2022–MAY 2025 227 TABLE 238 ZYDUS GROUP: COMPANY OVERVIEW 228 TABLE 239 ZYDUS GROUP: PRODUCTS OFFERED 229 TABLE 240 ZYDUS GROUP: PRODUCT APPROVALS, JANUARY 2022–MAY 2025 230 TABLE 241 BLISS GVS PHARMA LIMITED: COMPANY OVERVIEW 231 TABLE 242 BLISS GVS PHARMA LIMITED: PRODUCTS OFFERED 232 TABLE 243 CHURCH & DWIGHT CO., INC.: COMPANY OVERVIEW 233 TABLE 244 CHURCH & DWIGHT CO., INC.: PRODUCTS OFFERED 234 TABLE 245 BAUSCH HEALTH COMPANIES INC.: COMPANY OVERVIEW 235 TABLE 246 BAUSCH HEALTH COMPANIES INC.: PRODUCTS OFFERED 237 TABLE 247 ADCOCK INGRAM: COMPANY OVERVIEW 238 TABLE 248 ADCOCK INGRAM: PRODUCTS OFFERED 239 TABLE 249 ASPEN HOLDINGS: COMPANY OVERVIEW 240 TABLE 250 ASPEN HOLDINGS: PRODUCTS OFFERED 241 TABLE 251 JULPHAR: COMPANY OVERVIEW 242 TABLE 252 JULPHAR: PRODUCTS OFFERED 243 TABLE 253 HALEON GROUP OF COMPANIES: COMPANY OVERVIEW 245 TABLE 254 HALEON GROUP OF COMPANIES: PRODUCTS OFFERED 246 TABLE 255 LES LABORATOIRES SERVIER: COMPANY OVERVIEW 247 TABLE 256 LES LABORATOIRES SERVIER: PRODUCTS OFFERED 248 TABLE 257 PRESTIGE CONSUMER HEALTHCARE: COMPANY OVERVIEW 249 TABLE 258 PRESTIGE CONSUMER HEALTHCARE: PRODUCTS OFFERED 250 TABLE 259 VIATRIS INC.: COMPANY OVERVIEW 252 TABLE 260 VIATRIS INC.: PRODUCTS OFFERED 253 TABLE 261 GALEN LIMITED: COMPANY OVERVIEW 254 TABLE 262 GALEN LIMITED: PRODUCTS OFFERED 254 TABLE 263 MERIDIAN ENTERPRISES PVT. LTD.: COMPANY OVERVIEW 257 TABLE 264 MERIDIAN ENTERPRISES PVT. LTD.: PRODUCTS OFFERED 257 TABLE 265 COSETTE PHARMACEUTICALS: COMPANY OVERVIEW 259 TABLE 266 FLAGSHIP: COMPANY OVERVIEW 260 TABLE 267 OUBARI PHARMA: COMPANY OVERVIEW 261 TABLE 268 LAVINA PHARMACEUTICALS PVT. LTD.: COMPANY OVERVIEW 262 TABLE 269 NORWELL: COMPANY OVERVIEW 263 FIGURE 1 SUPPOSITORIES MARKET SEGMENTATION AND REGIONAL SCOPE 26 FIGURE 2 SUPPOSITORIES MARKET: YEARS CONSIDERED 28 FIGURE 3 SUPPOSITORIES MARKET: RESEARCH DESIGN 30 FIGURE 4 SUPPOSITORIES MARKET: KEY PRIMARY SOURCES 33 FIGURE 5 SUPPOSITORIES MARKET: INSIGHTS FROM PRIMARIES 34 FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS 34 FIGURE 7 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 35 FIGURE 8 SUPPOSITORIES MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS, 2024 35 FIGURE 9 SUPPOSITORIES MARKET SIZE ESTIMATION: CAGR ESTIMATION, 2024 36 FIGURE 10 TOP-DOWN APPROACH 37 FIGURE 11 BOTTOM-UP APPROACH 37 FIGURE 12 DATA TRIANGULATION METHODOLOGY 39 FIGURE 13 SUPPOSITORIES MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION) 42 FIGURE 14 SUPPOSITORIES MARKET, BY BASE, 2025 VS. 2030 (USD MILLION) 43 FIGURE 15 SUPPOSITORIES MARKET, BY PRESCRIPTION, 2025 VS. 2030 (USD MILLION) 43 FIGURE 16 SUPPOSITORIES MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION) 44 FIGURE 17 SUPPOSITORIES MARKET, BY PATIENT TYPE, 2025 VS. 2030 (USD MILLION) 44 FIGURE 18 GEOGRAPHICAL SNAPSHOT OF SUPPOSITORIES MARKET 45 FIGURE 19 INCREASING PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET 46 FIGURE 20 RECTAL SUPPOSITORIES SEGMENT AND US LED NORTH AMERICAN MARKET IN 2024 47 FIGURE 21 RECTAL SUPPOSITORIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 47 FIGURE 22 OLEAGINOUS/LIPOPHILIC BASES SEGMENT TO HAVE LARGEST MARKET SHARE DURING FORECAST PERIOD 48 FIGURE 23 PRESCRIPTION SUPPOSITORIES SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 48 FIGURE 24 CHINA TO REGISTER HIGHEST GROWTH IN SUPPOSITORIES MARKET FROM 2025 TO 2030 49 FIGURE 25 SUPPOSITORIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 50 FIGURE 26 REVENUE SHIFT AND NEW REVENUE POCKETS FOR SUPPOSITORIES MARKET 56 FIGURE 27 AVERAGE SELLING PRICE OF RECTAL SUPPOSITORIES, BY KEY PLAYER, 2025 (USD) 57 FIGURE 28 SUPPOSITORIES MARKET: VALUE CHAIN ANALYSIS 59 FIGURE 29 SUPPOSITORIES MARKET: ECOSYSTEM ANALYSIS 60 FIGURE 30 SUPPOSITORIES MARKET: INVESTMENT AND FUNDING SCENARIO, 2020–2024 62 FIGURE 31 SUPPOSITORIES MARKET: PATENT ANALYSIS, JANUARY 2014–MAY 2025 65 FIGURE 32 TOP APPLICANT COUNTRIES/REGIONS FOR SUPPOSITORIES PATENTS, JANUARY 2014–MAY 2025 66 FIGURE 33 SUPPOSITORIES MARKET: PORTER’S FIVE FORCES ANALYSIS 75 FIGURE 34 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE 77 FIGURE 35 KEY BUYING CRITERIA, BY TYPE 78 FIGURE 36 AI USE CASES 81 FIGURE 37 NORTH AMERICA: SUPPOSITORIES MARKET SNAPSHOT 124 FIGURE 38 ASIA PACIFIC: SUPPOSITORIES MARKET SNAPSHOT 149 FIGURE 39 REVENUE ANALYSIS OF TOP FIVE PLAYERS IN SUPPOSITORIES MARKET, 2022–2024 191 FIGURE 40 SUPPOSITORIES MARKET SHARE ANALYSIS, 2024 192 FIGURE 41 RANKING OF KEY PLAYERS IN SUPPOSITORIES MARKET, 2024 194 FIGURE 42 SUPPOSITORIES MARKET: BRAND/PRODUCT COMPARISON 194 FIGURE 43 EV/EBITDA OF KEY VENDORS 195 FIGURE 44 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 195 FIGURE 45 SUPPOSITORIES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 197 FIGURE 46 SUPPOSITORIES MARKET: COMPANY FOOTPRINT 198 FIGURE 47 SUPPOSITORIES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 203 FIGURE 48 SANDOZ GROUP AG: COMPANY SNAPSHOT (2024) 208 FIGURE 49 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2024) 211 FIGURE 50 CIPLA: COMPANY SNAPSHOT (2024) 214 FIGURE 51 SANOFI: COMPANY SNAPSHOT (2024) 217 FIGURE 52 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2024) 220 FIGURE 53 BAYER AG: COMPANY SNAPSHOT (2024) 223 FIGURE 54 NOVARTIS AG: COMPANY SNAPSHOT (2024) 226 FIGURE 55 ZYDUS GROUP: COMPANY SNAPSHOT (2024) 229 FIGURE 56 BLISS GVS PHARMA LIMITED: COMPANY SNAPSHOT (2024) 231 FIGURE 57 CHURCH & DWIGHT CO., INC.: COMPANY SNAPSHOT (2024) 233 FIGURE 58 BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT (2024) 236 FIGURE 59 ADCOCK INGRAM: COMPANY SNAPSHOT (2023) 238 FIGURE 60 ASPEN HOLDINGS: COMPANY SNAPSHOT (2023) 241 FIGURE 61 JULPHAR: COMPANY SNAPSHOT (2024) 243 FIGURE 62 HALEON GROUP OF COMPANIES: COMPANY SNAPSHOT (2024) 246 FIGURE 63 LES LABORATOIRES SERVIER: COMPANY SNAPSHOT (2023) 248 FIGURE 64 PRESTIGE CONSUMER HEALTHCARE: COMPANY SNAPSHOT (2024) 250 FIGURE 65 VIATRIS INC.: COMPANY SNAPSHOT (2024) 253

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們